TSE:HBP

Helix BioPharma Competitors

C$0.88
+0.03 (+3.53 %)
(As of 04/20/2021 01:58 PM ET)
Add
Compare
Today's Range
C$0.88
Now: C$0.88
C$0.88
50-Day Range
C$0.77
MA: C$0.84
C$0.92
52-Week Range
C$0.25
Now: C$0.88
C$1.60
Volume26,285 shs
Average Volume46,795 shs
Market CapitalizationC$124.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Helix BioPharma (TSE:HBP) Vs. BLU, TH, NRI, PLI, NEPT, and MDNA

Should you be buying HBP stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Helix BioPharma, including BELLUS Health (BLU), Theratechnologies (TH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), ProMetic Life Sciences (PLI), Neptune Wellness Solutions (NEPT), and Medicenna Therapeutics (MDNA).

Helix BioPharma (TSE:HBP) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Valuation and Earnings

This table compares Helix BioPharma and BELLUS Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/AN/AC($0.06)-16.00
BELLUS HealthC$15,000.0029,298.04C$-52,720,801.00C($0.67)-8.34

Helix BioPharma has higher earnings, but lower revenue than BELLUS Health. Helix BioPharma is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Helix BioPharma and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helix BioPharmaN/AN/AN/A
BELLUS HealthN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for Helix BioPharma and BELLUS Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helix BioPharma0000N/A
BELLUS Health01202.67

Summary

BELLUS Health beats Helix BioPharma on 3 of the 4 factors compared between the two stocks.

Helix BioPharma (TSE:HBP) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Valuation & Earnings

This table compares Helix BioPharma and Theratechnologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/AN/AC($0.06)-16.00
TheratechnologiesC$65.76 million6.47C$-35,948,380.00C($0.38)-11.84

Helix BioPharma has higher earnings, but lower revenue than Theratechnologies. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Helix BioPharma and Theratechnologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helix BioPharma0000N/A
Theratechnologies02002.00

Theratechnologies has a consensus price target of C$3.75, indicating a potential downside of 16.67%. Given Theratechnologies' higher probable upside, analysts clearly believe Theratechnologies is more favorable than Helix BioPharma.

Profitability

This table compares Helix BioPharma and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helix BioPharmaN/AN/AN/A
TheratechnologiesN/AN/AN/A

Summary

Theratechnologies beats Helix BioPharma on 3 of the 4 factors compared between the two stocks.

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Helix BioPharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.26C$-6,980,844.00C($0.61)-57.38
Helix BioPharmaN/AN/AN/AC($0.06)-16.00

Helix BioPharma has lower revenue, but higher earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Nuvo Pharmaceuticals Inc. (NRI.TO) and Helix BioPharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00
Helix BioPharma0000N/A

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Helix BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A
Helix BioPharmaN/AN/AN/A

ProMetic Life Sciences (TSE:PLI) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares ProMetic Life Sciences and Helix BioPharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
Helix BioPharmaN/AN/AN/AC($0.06)-16.00

Helix BioPharma has lower revenue, but higher earnings than ProMetic Life Sciences. Helix BioPharma is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for ProMetic Life Sciences and Helix BioPharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Helix BioPharma0000N/A

Profitability

This table compares ProMetic Life Sciences and Helix BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
Helix BioPharmaN/AN/AN/A

Summary

ProMetic Life Sciences beats Helix BioPharma on 2 of the 3 factors compared between the two stocks.

Neptune Wellness Solutions (TSE:NEPT) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares Neptune Wellness Solutions and Helix BioPharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neptune Wellness SolutionsC$52.78 million4.61C$-223,415,550.00C($1.35)-1.09
Helix BioPharmaN/AN/AN/AC($0.06)-16.00

Helix BioPharma has lower revenue, but higher earnings than Neptune Wellness Solutions. Helix BioPharma is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Neptune Wellness Solutions and Helix BioPharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neptune Wellness Solutions00103.00
Helix BioPharma0000N/A

Neptune Wellness Solutions presently has a consensus price target of C$4.63, indicating a potential upside of 214.63%. Given Neptune Wellness Solutions' higher probable upside, analysts plainly believe Neptune Wellness Solutions is more favorable than Helix BioPharma.

Profitability

This table compares Neptune Wellness Solutions and Helix BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neptune Wellness SolutionsN/AN/AN/A
Helix BioPharmaN/AN/AN/A

Summary

Neptune Wellness Solutions beats Helix BioPharma on 4 of the 5 factors compared between the two stocks.

Medicenna Therapeutics (TSE:MDNA) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Medicenna Therapeutics and Helix BioPharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicenna Therapeutics0000N/A
Helix BioPharma0000N/A

Profitability

This table compares Medicenna Therapeutics and Helix BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicenna TherapeuticsN/AN/AN/A
Helix BioPharmaN/AN/AN/A

Earnings and Valuation

This table compares Medicenna Therapeutics and Helix BioPharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/AN/AC($0.31)-15.60
Helix BioPharmaN/AN/AN/AC($0.06)-16.00

Helix BioPharma is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.


Helix BioPharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BLU
BELLUS Health
0.5$5.61+3.2%C$453.57 millionC$15,000.00-8.34
Theratechnologies logo
TH
Theratechnologies
0.7$4.50+0.2%C$425.70 millionC$65.76 million-11.84Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.18+0.5%C$400.57 millionC$76.09 million-57.38
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22
NEPT
Neptune Wellness Solutions
1.2$1.47+8.2%C$263.13 millionC$52.78 million-1.09Gap Up
MDNA
Medicenna Therapeutics
0.5$4.82+0.6%C$256.58 millionN/A-15.60
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89News Coverage
IMV logo
IMV
IMV
1.2$3.39+1.5%C$229.54 millionC$3,000.00-5.87
RVX
Resverlogix
0.7$0.89+2.2%C$212.93 millionN/A63.57Upcoming Earnings
News Coverage
FRX
Fennec Pharmaceuticals
0.5$7.85+2.9%C$210.10 millionC$170,000.00-8.21Gap Up
ATE
Antibe Therapeutics
1.3$4.27+6.3%C$206.60 millionC$9.33 million-5.43Gap Down
ONC
Oncolytics Biotech
1.2$3.80+4.7%C$200.52 millionN/A-6.79
IPA
ImmunoPrecise Antibodies
0.4$11.63+5.0%C$123.03 millionC$17.18 million-54.35
ACST
Acasti Pharma
0.8$0.53+3.8%C$88.79 millionC$81,000.0015.59News Coverage
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.60+1.7%C$66.76 millionC$11.64 million-11.76News Coverage
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
SBM
Sirona Biochem
0.5$0.36+4.2%C$58.80 millionC$123,870.00-27.69
PMN
ProMIS Neurosciences
0.5$0.18+0.0%C$55.07 millionC$1,787.00-9.00News Coverage
Gap Down
COV
Covalon Technologies
0.6$1.55+3.2%C$37.44 millionC$23.84 million-6.51
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.25+2.0%C$34.02 millionC$13.02 million-0.36
IGX
IntelGenx Technologies
0.9$0.53+1.9%C$30.87 millionC$1.54 million-6.54
QPT
Quest PharmaTech
0.8$0.11+4.8%C$21.76 millionC$38,871.000.16High Trading Volume
Gap Up
CZO
Ceapro
0.7$0.72+2.8%C$21.65 millionC$16.14 million21.82
CTX
Crescita Therapeutics
0.6$0.80+6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.20+2.6%C$14.12 millionC$1.34 million-5.57High Trading Volume
GSD
Devonian Health Group
0.5$0.28+7.1%C$13.96 millionC$1.59 million-5.83Gap Down
PAS
Pascal Biosciences
0.6$0.08+6.3%C$12.70 millionN/A-3.64Gap Up
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63+1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.33+3.0%C$10.16 millionC$4.12 million30.00Gap Down
HEM
Hemostemix
0.6$0.34+1.5%C$9.07 millionN/A-2.02Gap Down
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.38+2.6%C$6.94 millionC$5.60 million7.04
IOT
Innovotech
0.8$0.17+5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.69+3.5%C$4.48 millionN/A-1.19
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.83+1.6%C$0.00C$267.59 million51.46
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00News Coverage
Gap Down
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.